Inhibrx Biosciences, Inc. (NASDAQ: INBX)

Sector: Healthcare Industry: Biotechnology CIK: 0002007919
P/B 28.01
P/E -6.65
P/S 736.99
Market Cap 1.03 Bn
ROIC (Qtr) -96.55
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 106.91 Mn
Debt/Equity (Qtr) 2.90

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 153.09M provide 68.13x coverage of short-term debt 2.25M, demonstrating strong liquidity position and minimal refinancing risk.
  • Tangible assets of 177.47M provide robust 6.58x coverage of other current liabilities 26.96M, indicating strong asset backing.
  • Cash reserves of 153.09M provide robust 4.25x coverage of current liabilities 35.98M, indicating strong short-term solvency.
  • Strong cash position of 153.09M provides 5.68x coverage of other current liabilities 26.96M, indicating excellent liquidity.
  • Cash position of 153.09M represents healthy 1.22x of working capital 125.44M, demonstrating strong operational liquidity.

Cons

  • Investment activities of (44000) provide weak support for R&D spending of 121.05M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (143.39M) shows concerning coverage of stock compensation expenses of 11.38M, with a -12.60 ratio indicating potential earnings quality issues.
  • Free cash flow of (143.44M) provides weak coverage of capital expenditures of 44000, with a -3259.91 ratio suggesting additional external financing needs for growth initiatives.
  • Operating cash flow of (143.39M) provides minimal -71696x coverage of tax expenses of 2000, suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Operating earnings of (146.07M) show weak coverage of depreciation charges of 4.41M, with a -33.11 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 5.36 12.31
EV to Cash from Ops. -6.64 23.25
EV to Debt 8.91 738.44
EV to EBIT -6.52 -9.16
EV to EBITDA -6.36 6.95
EV to Free Cash Flow [EV/FCF] -6.64 21.90
EV to Market Cap 0.92 65.67
EV to Revenue 680.01 227.32
Price to Book Value [P/B] 28.01 22.34
Price to Earnings [P/E] -6.65 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -16.21 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 99.27 -27.13
Cash and Equivalents Growth (1y) % -22.03 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -108.78 -46.93
EBITDA Growth (1y) % 59.12 -1.68
EBIT Growth (1y) % -108.78 -56.45
EBT Growth (1y) % -109.45 -12.70
EPS Growth (1y) % -110.76 -28.31
FCF Growth (1y) % 32.83 -31.90
Gross Profit Growth (1y) % -19.26 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.01 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 4.25 3.85
Current Ratio 4.49 7.27
Debt to Equity Ratio 2.90 0.40
Interest Cover Ratio -16.21 841.00
Times Interest Earned -16.21 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -10,118.60 -18,234.31
EBIT Margin % -10,433.79 -18,580.80
EBT Margin % -11,077.43 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -11,077.60 -19,439.22